Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

NCT02908100 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02908100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02908100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 19, 2017
Completion date
July 16, 2019
Enrollment
260 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus